TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03331380

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI scans - obj 4
Description: For objective 4 (comparative scanning of patients), subjects with known or suspected disease, including neurological, musculoskeletal disease, abdominal or lung disease, will undergo two MR examinations on two different MRI scanners (investigational low SAR CMR and conventional MR).
Study: NCT00775788

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Fat Grafting to Breasts
Description: Fat injection of Fat to breasts

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Fat Grafting to Breasts
Description: Fat injection of Fat to breasts

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Fat Grafting to Breasts
Description: Fat injection of Fat to breasts
Study: NCT01612416

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RS-3000 OCT measurements
Description: Ganglion cell, retinal nerve fiber layer and retinal thickness measurements of normal subjects, primary open angle glaucoma and normal tension glaucoma patients using RS-3000 OCT RetinaScan

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RS-3000 OCT measurements
Description: Ganglion cell, retinal nerve fiber layer and retinal thickness measurements of normal subjects, primary open angle glaucoma and normal tension glaucoma patients using RS-3000 OCT RetinaScan

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RS-3000 OCT measurements
Description: Ganglion cell, retinal nerve fiber layer and retinal thickness measurements of normal subjects, primary open angle glaucoma and normal tension glaucoma patients using RS-3000 OCT RetinaScan
Study: NCT01751542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness + Residential Treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Residential treatment alone
Study: NCT01207999

Intervention type: PROCEDURE
Intervention: Collection of cervical cancer tissue samples
Description: Cervical samples will be tested for histopathology diagnosis and human papillomavirus DNA testing.

Intervention type: OTHER
Intervention: Data collection
Description: Questionnaire completion
Study: NCT02260544

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride Liposome Injection
Description: 50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation , After completion of Cycle 2 ( Day 28) , patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome injection upto 4 more cycles if tolerance permits under guidance of their attending physicians.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride Liposome Injection
Description: 50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation , After completion of Cycle 2 ( Day 28) , patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome injection upto 4 more cycles if tolerance permits under guidance of their attending physicians.
Study: NCT04158752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Injection of study drug at 3 timepoints (day 30, day 60, day 90)
Study: NCT05993715

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate supplementation
Description: Participants ingested 2 × 70 mL/day shots of concentrate nitrate-rich (\~12.8 mmol/day nitrate) or nitrate-depleted (\~0.08 mmol/day nitrite) beetroot juice (Beet It, James White Drinks Ltd., Ipswich, UK). Two shots were supplemented for 5 days; one each morning (\~9 am) and one each evening (\~9 pm) except for the day of the experimental trial when both shots were taken together 2.5 h before the experimental trial.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementtaion
Description: 2 × 70 mL/day shots of concentrate nitrate-depleted (\~0.08 mmol/day NO3-) beetroot juice. Two shots were supplemented for 5 days; one each morning (\~9 am) and one each evening (\~9 pm) except for the day of the experimental trial when both shots were taken together 2.5 h before the experimental trial.
Study: NCT03953820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam Buccal Film
Description: Diazepam Buccal Film administered on inner aspect of the cheek at the recommended dose regimen (10 mg to 17.5 mg according to body weight) following ingestion of a moderate fat meal and following ingestion of a high-fat meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam Buccal Film
Description: Diazepam Buccal Film administered on inner aspect of the cheek at the recommended dose regimen (10 mg to 17.5 mg according to body weight) following ingestion of a moderate fat meal and following ingestion of a high-fat meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam Buccal Film
Description: Diazepam Buccal Film administered on inner aspect of the cheek at the recommended dose regimen (10 mg to 17.5 mg according to body weight) following ingestion of a moderate fat meal and following ingestion of a high-fat meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diastat® Rectal Gel (Valeant Pharmaceuticals USA)
Description: Diastat Rectal Gel administered rectally according to product label administration and dosing instructions (10 mg to 20 mg according to body weight) following ingestion of a moderate-fat meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diastat® Rectal Gel (Valeant Pharmaceuticals USA)
Description: Diastat Rectal Gel administered rectally according to product label administration and dosing instructions (10 mg to 20 mg according to body weight) following ingestion of a moderate-fat meal.
Study: NCT03700593

Intervention type: DEVICE
Intervention: Single Port Robotic Colorectal Surgery
Description: Single Port Robotic Colorectal Surgery
Study: NCT04435691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT00448448

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brace
Description: Brace (TLSO) applied for at least 18 hours per day. Wear time measured using a temperature monitor. Clinical, radiographic, and self-report follow-up every 6 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Clinical, radiographic, and self-report follow-up every 6 months.
Study: NCT03501628

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Supplementation twice daily (1 serving dose per consumption) of maltodextin while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-leucine + maltodextrin
Description: Supplementation twice daily (1 serving dose per consumption) of L-leucine + maltodextin while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein concentrate
Description: Supplementation twice daily (1 serving dose per consumption) of whey protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed whey protein concentrate
Description: Supplementation twice daily (1 serving dose per consumption) of hydrolyzed whey protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy protein concentrate
Description: Supplementation twice daily (1 serving dose per consumption) of soy protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
Study: NCT02412670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Administered subcutaneously

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephroureterectomy
Description: Undergo nephroureterectomy and lymph node dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephroureterectomy
Description: Undergo nephroureterectomy and lymph node dissection
Study: NCT01425476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
Study: NCT01756066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Different levels of cost sharing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Different levels of cost sharing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Different levels of cost sharing
Study: NCT00983840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Eats
Description: 8-session web-based program on healthy eating for African American families

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Family Eats
Description: 8-session web-based program on healthy eating for African American families
Study: NCT03441893

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: parasitological diagnostics (coproscopy)
Description: Three stool samples for parasitological examination will be taken from ulcerative colitis patients at 1-2 days interval.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: parasitological diagnostics (coproscopy)
Description: Three stool samples for parasitological examination will be taken from ulcerative colitis patients at 1-2 days interval.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: parasitological diagnostics (coproscopy)
Description: Three stool samples for parasitological examination will be taken from ulcerative colitis patients at 1-2 days interval.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: parasitological diagnostics (coproscopy)
Description: Three stool samples for parasitological examination will be taken from ulcerative colitis patients at 1-2 days interval.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide 500Mg Oral Tablet
Description: Tab. nitazoxanide by a 1.0 g/day (two pills) twice over orally for 14 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet
Description: Tab. nitazoxanide by a 1.0 g/day (one pill - 500 mg) twice over orally and mesalazine 1.5 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine 250Mg
Description: Tab. mesalazine ≥3 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tabletes
Description: Tab. Placebo (shugar pills) will be given to the participants
Study: NCT00839878

Intervention type: OTHER
Intervention: No treatment given
Description: Subject will only fill out a questionaire when entering the observational study.
Study: NCT00718289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Citrate dialysate
Description: dialysis fluid composition for Citrate (C) and Acetate (A): acetate \[3.0 mmol/L in A and 0.3 in C\], citrate \[0 mmol/L in A and 0.8 in C\]

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acetate dialysate
Description: dialysis fluid composition for Citrate (C) and Acetate (A): acetate \[3.0 mmol/L in A and 0.3 in C\], citrate \[0 mmol/L in A and 0.8 in C\]
Study: NCT02842112

Intervention type: OTHER
Intervention: PBSC mobilization and leukapheresis
Description: Mobilization and harvest of autologous PBSCs was scheduled during the recovery phase after the consolidation course. Granulocyte colony stimulating factor (G-CSF) (150 µg/m2/day) was given by daily subcutaneous injection from day 20 of the chemotherapy course until completion of the blood stem cell collections. PBSC collections were performed on 1 - 5 consecutive days during the hematopoietic recovery phase, as soon as the leukocyte count exceeded 2x 109/L.~Collections were performed after induction or after consolidation. In cases in which the minimum number of CD34+ cells was not collected, an additional mobilization was performed in steady state.~Harvesting was performed using continuous flow blood cell separators. Cells were stored in liquid nitrogen until use, according to standard techniques.

Intervention type: OTHER
Intervention: PBSC mobilization and leukapheresis
Description: Mobilization and harvest of autologous PBSCs was scheduled during the recovery phase after the consolidation course. Granulocyte colony stimulating factor (G-CSF) (150 µg/m2/day) was given by daily subcutaneous injection from day 20 of the chemotherapy course until completion of the blood stem cell collections. PBSC collections were performed on 1 - 5 consecutive days during the hematopoietic recovery phase, as soon as the leukocyte count exceeded 2x 109/L.~Collections were performed after induction or after consolidation. In cases in which the minimum number of CD34+ cells was not collected, an additional mobilization was performed in steady state.~Harvesting was performed using continuous flow blood cell separators. Cells were stored in liquid nitrogen until use, according to standard techniques.

Intervention type: OTHER
Intervention: PBSC mobilization and leukapheresis
Description: Mobilization and harvest of autologous PBSCs was scheduled during the recovery phase after the consolidation course. Granulocyte colony stimulating factor (G-CSF) (150 µg/m2/day) was given by daily subcutaneous injection from day 20 of the chemotherapy course until completion of the blood stem cell collections. PBSC collections were performed on 1 - 5 consecutive days during the hematopoietic recovery phase, as soon as the leukocyte count exceeded 2x 109/L.~Collections were performed after induction or after consolidation. In cases in which the minimum number of CD34+ cells was not collected, an additional mobilization was performed in steady state.~Harvesting was performed using continuous flow blood cell separators. Cells were stored in liquid nitrogen until use, according to standard techniques.
Study: NCT02771652

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: e-training
Description: The e-training intervention is a home-based aerobic and resistance training program. Resistance training was prescribed twice weekly for a period of 12 weeks. No special equipment was necessary except an elastic exercise band or a large gymnastic ball. In addition, endurance training was to be carried out once a week. Training intensity was regulated by the participant's subjective, perceived exertion, which was rated between 6 and 20 on the BORG Scale. The form of activity for the endurance training was freely selected, duration (between 10-60 min) was adjusted to individual fitness levels. Therapists aimed at eliciting a BORG Feedback of between 11 (fairly light) and 16 (hard). The exercise training was home-based and supervised via the internet. Participants continued exercise training for another 12 weeks after the 3month assessment.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: After the initial assessment on entry, those assigned to the control group were instructed to maintain their previous physical activity behaviour. After waiting three months, they received the same e-training intervention as the intervention group had received from the start.
Study: NCT03385382

Intervention type: DRUG
Intervention: Dexamethasone intravitreal implant 0.7 mg
Description: Intravitreal Implant of dexamethasone

Intervention type: DRUG
Intervention: Ranibizumab Injection
Description: Injection of ranibizumab
Study: NCT04494555

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Static socket
Description: For the static socket configuration, both the microprocessor control and user control are disabled, and the panels are positioned in their flush configuration to create the user's as-prescribed socket shape.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: User adjusted socket
Description: Sockets are configured for user control by disabling automated control and enabling push buttons on the side of the socket to adjust socket size. Each button push effects a socket size change of approximately 0.3% volume. An upper button effects a socket size increase, and a lower button a socket size decrease. The buttons are countersunk so reduce risk of accidental pushes, and they do not function unless the user is stationary. An additional button push will not be executed until motor motion from the prior push has been completed. If a button is continuously held then the motor will continue moving until the button is released. Limits are set on cable length to ensure that sockets sizes threatening to the user's residual limb (too tight) are avoided. The push buttons effect inner-loop control that operates completely within the mechanism, achieving high-resolution adjustment of cable length with minimal error.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microprocessor-adjusting sockets
Description: A strategy for automatically controlling the size of the socket during walking to compensate for unknown changes in limb volume will be used. The controller is essentially a regulator that continuously measures socket fit, and adjusts the socket to maintain a prescribed reference set point. Because the fit is automatically sustained, the prosthesis user is unaware of its operation.
Study: NCT04684914

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepTcell
Description: Intramuscular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection
Study: NCT03286712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renogen
Description: Administration of erythropietin alpha to see the effect on the hemoglobin level and vascular reactivity
Study: NCT00985556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tegafur-gimeracil-oteracil potassium
Description: Given orally
Study: NCT04556656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pridopidine
Description: Pridopidine hard gelatin capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pridopidine-matching placebo hard gelatin capsule
Study: NCT02028585

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-fat milk group
Study: NCT02411383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuRx Diaphragm Pacing System
Description: NeuRx Diaphragm Pacing System electrodes are placed in the diaphragm during lung transplant surgery. The diaphragm will be continually paced until the patient is free from the ventilator or the patient is discharged from the ICU whichever. Diaphragm measurements are taken daily to assess tolerability and pacing success.
Study: NCT04348656

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: Patients will receive 500 mL of convalescent plasma (from one single-donor unit of 500 mL or 2 units of 250 mL from 1-2 donations) collected by apheresis from donors who have recovered from COVID-19 and frozen (1 year expiration date from date of collection). The plasma unit will be thawed as per standard blood bank procedures and infused into the patient slowly over 4 hours. When administering 2 units of 250 mL, the 2nd unit will be administered after the first, and no longer than 12 hours later. The patient will be monitored for adverse events as per each site's policies.
Study: NCT01532713

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oxygen administration
Description: nasal O2 5L/min via nasal cannula
Study: NCT03056976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-implant mandibular overdenture
Description: Complete mandibular denture retained by a single midline implant
Study: NCT01047579

Intervention type: DRUG
Group type: OTHER
Intervention: Rivastigmine transdermal
Study: NCT02560974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered orally at 1000 mg/m\^2 BID on Days 1 to 15 of a 3-week cycle, for 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered as an IV infusion, 130 mg/m\^2 on Day 1 of each 3-week cycle for 8 cycles.
Study: NCT01021241

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Uricase-PEG 20
Description: Intravenous infusion of Uricase-PEG 20 over one hour; no premedication
Study: NCT03056976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two-implant mandibular overdenture
Description: Complete mandibular denture retained by two implants in the canine region

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed mandibular denture
Description: A fixed mandibular denture retained by four implants
Study: NCT03488121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Poster
Description: Posters contain inspirational messages and pictures highlighting the important and unique roles that patients and physicians can play in reducing unnecessary care and health care costs. These posters will be placed in physician offices.
Study: NCT03627741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: A concentration of 40 mg/ml of Triamcinolone Acetonide will be used for injections with a total dose of 120 mg of Triamcinolone given per injection. The injections will be performed under ultrasound guidance by a fellowship-trained musculoskeletal radiologist. The injection locations will be left to the discretion of the radiologist with the request to attempt to distribute the drug throughout the tumor. A total of three injections will be performed at six week intervals.